Curatis Holding Ag · SIX:CURN
Curatis — Merger or Acquisition (January 2024)
21 slides from Curatis's merger presentation, Jan 29, 2024
Slide 1: Curatis – Kinarus Company Presentation & Transaction Summary
Entwurf Vertraulich CURATIS – KINARUS Company Presentation & Transaction Summary 29 January 2024
Slide 2: Vision: To become a leading European Specialist Medicines Company
Vision: To become a leading European Specialist Medicines Company by focusing on the acquisition, development and commercialization of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases
Slide 3: Background on the transaction
Background on the transaction § Curatis is a Swiss Specialist Medicines Company founded in 2002 § Curatis is privately held and financially independent § Curatis Distribution Business § 33 Medicines § Revenue generating, profitable and cash flow positive § Curatis Development Business § 1 late-stage
Slide 4: Investment Case
Investment Case § Curatis has balanced, low risk business model § Experienced board and management team with with a mix of distribution and drug development track record in development and commercialization Curatis is a activities of Orphan Drug products Experienced European Board and Specialty § Ma
Slide 5: Speciality Medicines Distribution Business Strategy
Speciality Medicines Distribution Business Strategy Distribution of third-party products focused on rare diseases and specialty medicines Cash Flow Generating Base Business Examples of Products Distributed § The Base Business of Curatis is a Swiss Specialist Medicines Distribution Business, whereby
Slide 6: Development Business Strategy – Ultra Orphan Drugs in Focus
TOM REWORK Development Business Strategy – Ultra Orphan Drugs in Focus Rare diseases are harbored by a small number of patients in a defined geographical area. However, the criteria to define rare diseases may vary from region to region such as affecting fewer than 200,000 people (6.4 in 10000 peopl
Slide 7: Advantages of Orphan Drug Development
CHECK DATA IF Advantages of Orphan Drug Development FROM 2023 REPORT Factsheet orphan drug development Attractive orphan drug market Pipeline of Orphan vs. Non Orphan Drugs in USDbn) 160 144.2 § Worldwide orphan drug market estimated to 140 be a total $241bn by 2026 120 63% CAG R = 92.4 100 § New Or
Slide 8: Oncology remains #1 Therapy area for Orphan Drugs
Oncology remains #1 Therapy area for Orphan Drugs Share of Worldwide Orphan Drug Sales -2021 Share of Worldwide Orphan Drug Sales - 2026E Oncology Oncology Blood 6% Blood 6% Central Nervous System Central Nervous System 6% Various 6% Various Cardiovascular 48% Cardiovascular 47% 7% 9% Respiratory Re
Slide 9: Migraine with Aura and Medication Overuse Headache - A Strongly Growing Market
Migraine with Aura and Medication Overuse Headache REVIEW RR - A Strongly Growing Market Factsheet Migraine with Aura and Medication Overuse Headache Worldwide migraine epidemic in the making § Migraine and TTH is a global health problem currently affecting more than 1 600 Migraine is number 3 illne
Slide 10: Development Pipeline
Development Pipeline Preclinical I IIa IIb Pivotal Phase III MA POC Peritumoral Brain C-PTBE-01 1 pivotal trial Edema in children envisaged Pivotal Phase III with relatively small C-AM-01 patient number, Migraine with Aura 24-36 months including preparation Medication Overuse Headache C-MOH-01 Vario
Slide 11: C-PTBE-01: Peritumoral Brain Edema in Children
A. C-PTBE-01: Peritumoral Brain Edema in Children § Peritumoral brain Edema (PTBE) in children § For certain malignant brain tumors in children no curative therapy is available § Average survival time after diagnosis: 9 months § Main treatment goal: quality of life § Tumor induced edema (PTBE) is a
Slide 12: C-AM-01: Migraine with Aura
B. C-AM-01: Migraine with Aura § Migraine Auras are the sensory symptoms (neurologic, gastrointestinal, and autonomic) that can occur before or during a migraine episode § Symptoms can § include flashes of light, blind spots, or tingling in the hands or face § look like a more serious condition, suc
Slide 13: C-MOH-01: Medication Overuse Headache
C. C-MOH-01: Medication Overuse Headache § Headache characterized by worsening as result from Medication Overuse § Frequent and prolonged use of medication for the acute treatment § Paradoxical effect: Analgesic medication increase headache frequency/intensity § No approved drug for treatment/preven
Slide 14: Development Roadmap
Development Roadmap Various potentially significant value inflection points Main development 2024E 2025E 2026E 2027E 2028E programs C-PTBE-01 Orphan Drug Designation Pivotal Study Phase III Licensing Deal US NDA FDA NDA EMA Potential Rare Pediatric Disease Voucher Commercialization in US Commerciali
Slide 15: Board of Directors and Executive Management Team
Board of Directors and Executive Management Team Board of Directors (subject to approval at the Company’s EGM) in February 2024 Dr. Marian Borovsky Günter Graubach § Chairman of the Board of Directors § Executive Member of the Board of Directors § Previously Group General Counsel of Actelion § Previ
Slide 16: Envisaged Transaction Structure
Envisaged Transaction Structure 1 Financing Transaction § Potential Investors to invest up to CHF5m into Curatis AG as Mandatory Exchangeable Loan Note (the “Loan Note”) Approx 3,000 Shareholders 10 Shareholders I1 In § The Loan Note is to be exchanged 2months post Closing of the Business Combinatio
Slide 17: Transaction Highlights: Curatis & Kinarus
Transaction Highlights: Curatis & Kinarus § Kinarus Therapeutics Holding AG (in Liquidation) is listed on SIX Swiss Exchange (Symbol: KNRS), based in Basel (Canton BS) Involved § Curatis AG (“Curatis”) is privately-held, based in Liestal, BL Entities § Kinarus Holding to continue trading on SIX Swis
Slide 18: Transaction Highlights: Curatis & Kinarus
Transaction Highlights: Curatis & Kinarus § Curatis and its advisors have worked closely with the bankruptcy administration of Basel-Stadt § Following the outcome of a Schuldenruf, measures have been taken to free up Kinarus Holding from any liability claim § Thereafter, the Board of Directors of Ki
Slide 19: Thank you
Thank you page 18
Slide 20: Important Notice
Important Notice THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This presentation (the
Slide 21: Slide 21